(bren TUX i mab ve DOE tin) Brand: Adcetris
• You must not receive brentuximab vedotin if you are allergic to it, or if you are also receiving other cancer medication called bleomycin (Blenoxane).
• Some people receiving a brentuximab vedotin injection have had a reaction to the infusion (when the medication is injected into the vein). Tell your caregiver right away if you feel nauseated, itchy, or if you have a fever, chills, cough, or trouble breathing during the injection. Infusion reactions often occur within the first 24 hours after the start of your brentuximab vedotin infusion.
• Brentuximab vedotin can lower blood cells that help your body fight infections and help your blood clot. Your blood may need to be tested often. Avoid being around people who are sick or have infections. Avoid activities that may magnify your risk of bleeding injury. Speak your doctor at once if you develop signs of infection.
• While using brentuximab vedotin, you may need frequent blood trials at your doctor's office.
• Brentuximab vedotin may reason a serious viral infection of the brain that can lead to disability or death. Call your doctor right away if you announcement any change in your mental state, problems with speech or walking, or decreased vision. These symptoms may start gradually and get worse quickly.
• Brentuximab vedotin is a cancer medicine that interferes with the growth and spread of cancer cells in the body.
• Brentuximab vedotin is used to treat Hodgkin's lymphoma or anaplastic big cell lymphoma.
• Brentuximab vedotin is given after a stem cell transplant or another cancer medications have been tried without successful treatment.
• Brentuximab vedotin may also be used for purposes not listed in this medicine guide.
• You must not receive brentuximab vedotin if you are allergic to it, or if you are also receiving other cancer medication called bleomycin (Blenoxane).
• To create certain you can safely use brentuximab vedotin, speak your doctor if you have any of these another conditions:
· liver disease;
· kidney disease;
· systemic lupus erythematosus (SLE);
· lung malady or a breathing disorder;
· a weak immune system; or
· if you have used determined arthritis medicines in the past that were not effective, including adalimumab (Humira), certolizumab (Cimzia), golimumab (Simponi), etanercept (Enbrel), or infliximab (Remicade).
• FDA pregnancy category D. Do not receive brentuximab vedotin if you are pregnant. It could harm the unborn child. Use effective birth control, and speak your doctor if you become pregnant during treatment.
• It is not known whether brentuximab vedotin passes into breast milk or if it could harm a nursing child. You must not breast-feed while you are using brentuximab vedotin.
• Brentuximab vedotin is injected into a vein through an IV. You will receive this injection in a clinic or hospital setting.
• Till you receive brentuximab vedotin, you may be given another medications to prevent determined side effects that brentuximab vedotin can cause.
• Brentuximab vedotin is generally given once each 3 weeks for up to 16 treatment cycles. Follow your doctor's dosing instructions very carefully.
• While using brentuximab vedotin, you may need frequent blood trials at your doctor's office.
• Brentuximab vedotin can lower blood cells that help your body fight infections and help your blood clot. This can create it easier for you to bleed from an injury or get sick from being near others who are ill.
• If you need surgery, speak the surgeon onward of time that you are using brentuximab vedotin.
• Call your doctor if you miss an appointment for your brentuximab vedotin injection.
• Search abnormal medical attention or call the Poison Help line at 1-800-222-1222.
• Overdose symptoms may include severe forms of some of the side effects listed in this medicine guide.
• Avoid being around people who are sick or have infections. Speak your doctor at once if you develop signs of infection.
• Some people receiving a brentuximab vedotin injection have had a reaction to the infusion (when the medication is injected into the vein). Tell your caregiver right away if you feel nauseated, itchy, or if you have a fever, chills, cough, or trouble breathing during the infusion. Infusion reactions often occur within the first 24 hours after the start of your brentuximab vedotin infusion.
• Get abnormal medical help if you have any of these signs of an allergic reaction: hives; wheezing, chest tightness, trouble breathing; swelling of your person, lips, tongue, or throat.
• Brentuximab vedotin increases the risk of a serious viral infection of the brain that can lead to disability or death. This risk is higher if you have a weak immune system or are receiving determined medicines. Call your doctor right away if you have symptoms such as a change in your mental state, problems with speech or walking, or decreased vision. These symptoms may start gradually and get worse quickly.
• Call your doctor at once if you have any of these another serious side effects, even if they occur different months after you receive brentuximab vedotin, or after your treatment ends.
· numbness, weakness, burning pain, tingly feeling, or loss of feeling in your arms or legs;
· fever, chills, body aches, flu symptoms, sores in your mouth and throat;
· pale skin, feeling light-headed or short of breath, rapid heart course, trouble concentrating;
· light bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin;
· lower back pain, blood in your urine;
· pain or burning when you urinate, urinating smaller than normal or not at all;
· numbness or tingling near your mouth;
· muscle weakness, tightness, or contraction, overactive reflexes;
· quick or slow heart course, weak pulse, feeling short of breath, confusion, fainting; or
· severe skin reaction -- fever, sore throat, swelling in your person or tongue, burning in your eyes, skin pain, followed by a red or purple skin rash that spreads (especially in the person or upper body) and causes blistering and peeling.
• Smaller serious side effects may include:
· weary feeling;
· stomach pain, nausea, vomiting;
· diarrhea, constipation, weight loss;
· swelling in your hands or feet;
· mild rash or itching;
· dry skin, hair loss;
· headache, dizziness, anxiety;
· muscle spasm, muscle or joint pain; or
· night sweats, sleep problems (insomnia).
• This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may message side effects to FDA at 1-800-FDA-1088.
• Speak your doctor about all medications you use, and those you start or stop using during your treatment with brentuximab vedotin, especially:
· conivaptan (Vaprisol);
· imatinib (Gleevec);
· isoniazid (for treating tuberculosis);
· nefazodone;
· an antibiotic such as clarithromycin (Biaxin), erythromycin (E.E.S., EryPed, Ery-Tab, Erythrocin, Pediazole), or telithromycin (Ketek);
· antifungal medicine such as itraconazole (Sporanox), ketoconazole (Nizoral), miconazole (Oravig), or voriconazole (Vfend);
· heart or blood pressure medicine such as nicardipine (Cardene) or quinidine (Quin-G); or
· HIV/AIDS medication such as atazanavir (Reyataz), boceprevir (Victrelis), delavirdine (Rescriptor), fosamprenavir (Lexiva), indinavir (Crixivan), nelfinavir (Viracept), ritonavir (Norvir, Kaletra), saquinavir (Invirase), or telaprevir (Incivek).
• This list is not complete. Another drugs may interact with brentuximab vedotin, including prescription, over-the-counter, vitamin, and herbal commodity. Not all possible interactions are listed in this medicine manual.
• Your doctor or pharmacist can provide more information about brentuximab vedotin.
Remember, hold this and all another medicines out of the reach of children, never share your medicines with others, and use this medicine only for the indication prescribed.
Disclaim: Each effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses external of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way must be construed to indicate that the drug or drug combination is safety, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the help of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.